FZD7-Targeted Nanoparticles to Enhance Doxorubicin Treatment of Triple-Negative Breast Cancer
ACS Omega · 26.03.2024 · 9 (12) · 14323-14335
DOI: 10.1021/acsomega.3c10275 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Omega, online erschienen am 16.03.2024. Verfasst von Elise C Hoover und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Delaware, Newark, Delaware 19713, United States. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, University of Delaware.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Biomedical Engineering, University of Delaware, Newark, Delaware 19713, United States.
- Department of Materials Science and Engineering, University of Delaware, Newark, Delaware 19716, United States.
- Helen F. Graham Cancer Center and Research Institute, Newark, Delaware 19713, United States.
ORCID-Profile: Elise C Hoover, Emily S Day
Förderung
- NCI NIH HHS
- National Cancer Institute
- University of Delaware
Zitieren
APA
Hoover, E. C., Ruggiero, O. M., Swingler, R. N., & Day, E. S. (2024). FZD7-Targeted Nanoparticles to Enhance Doxorubicin Treatment of Triple-Negative Breast Cancer. ACS Omega, 9(12), 14323-14335. https://doi.org/10.1021/acsomega.3c10275
Vancouver
Hoover EC, Ruggiero OM, Swingler RN, Day ES. FZD7-Targeted Nanoparticles to Enhance Doxorubicin Treatment of Triple-Negative Breast Cancer. ACS Omega. 2024;9(12):14323-14335. doi:10.1021/acsomega.3c10275
BibTeX
@article{Hoover2024,
author = {Hoover, Elise C and Ruggiero, Olivia M and Swingler, Rachel N and Day, Emily S},
title = {FZD7-Targeted Nanoparticles to Enhance Doxorubicin Treatment of Triple-Negative Breast Cancer},
journal = {ACS Omega},
year = {2024},
volume = {9},
number = {12},
pages = {14323--14335},
doi = {10.1021/acsomega.3c10275}
}
EUVIMED